Intrinsiqs

Is Contineum Therapeutics, Inc. overvalued?

Contineum Therapeutics, Inc. (CTNM) — key valuation metrics and fundamentals.

No verdict
Price
$12.73
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$478.9M
Dividend yield
0.0%
Return on equity
-24.7%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CTNM's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.